Takeda Signs $50M Deal with Enterome for Crohn’s Disease Treatment
- Posted by ISPE Boston
- On October 25, 2018
Enterome, a clinical-stage French biotech with its U.S. headquarters in Cambridge, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical. Enterome is developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer. The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, […]
Read More